Dova Pharmaceuticals Inc is the United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.
Quote | Dova Pharmaceuticals Inc. (NASDAQ:DOVA)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $28.04 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/18/2019 04:31:07 pm |
News | Dova Pharmaceuticals Inc. (NASDAQ:DOVA)
The investor of today does not profit from yesterday's growth. - Warren Buffett Amgen (AMGN) and GlaxoSmithKline (GSK) are both huge pharmaceutical companies, but as companies grow bigger, ventures for future growth can become scarce. The success of any business depends on the existing pro...
Merger activity increased with seven new deals announced and two deals closing. Deal Statistics New Deals The acquisition of Carbonite (CARB) by Open Text Corporation (OTEX) for $1.42 billion or $23.00 per share in cash. We added CARB as a potential deal to the Deals in the Work...
Message Board Posts | Dova Pharmaceuticals Inc. (NASDAQ:DOVA)
Subject | By | Source | When |
---|---|---|---|
znewcar1: DOVA 38% v10M c27.95 f28M interesting day chart | znewcar1 | investorshangout | 09/30/2019 9:32:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Dova Pharmaceuticals Inc. Company Name:
DOVA Stock Symbol:
NASDAQ Market:
Dova Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / October 30, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Jagged Peak Energy Inc ( JAG ) related to...
NEW YORK, NY / ACCESSWIRE / October 19, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . ( RARX ) related to i...
NEW YORK / ACCESSWIRE / October 17, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Ra Pharmaceuticals, Inc . (NASDAQ: RARX ) relate...